World Library  
Flag as Inappropriate
Email this Article


Systematic (IUPAC) name
Clinical data
Pregnancy cat.
Legal status
  • Prescription only
Routes Oral
Pharmacokinetic data
Bioavailability 80%
peak at 4 hours[1]
Metabolism hepatic (CYP3A4 & CYP2C19)
Half-life 35 hours
Excretion Mostly as unmetabolized citalopram, partly DCT and traces of DDCT in urine
CAS number  YesY
ATC code N06
ChemSpider  YesY
Chemical data
Formula C20H21FN2O 
Mol. mass 324.392 g/mol

Citalopram ( or ; brand names: Celexa, Cipramil) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration (FDA) approval to treat major depression,[1] which it received in 1998[2] and is prescribed off-label for other conditions. In Australia, the UK, Germany, Portugal, Poland, and most European countries it is licensed for depressive episodes and panic disorder with or without agoraphobia. In Spain it is also used for obsessive-compulsive disorder.

Medical uses

Citalopram HBr tablets in 20 mg (coral, marked 508) and 40 mg (white, marked 509), and a United States one-cent coin (size 19.05mm/0.75").


In NICE (National Institute for Health and Clinical Excellence) ranking of 10 antidepressants for efficacy and cost-effectiveness[28] citalopram is fifth in effectiveness (after mirtazapine, escitalopram, venlafaxine and sertraline) and fourth in cost effectiveness. The ranking results were based on the meta analysis by Andrea Cipriani[29] In another analysis by Cipriani citalopram turned out to be more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however it seemed to be less efficacious than escitalopram.[5]

Evidence for effectiveness of citalopram for treating depression in children is equivocal.[30][31]

There has been controversy regarding the efficacy of antidepressants in treating depression depending on its severity and duration, as discussed in the Selective Serotonin Reuptake Inhibitor article.

Panic disorder

Citalopram is licensed in the UK and other European countries [32][33] for panic disorder, with or without agoraphobia. The dose is 10 mg/d for a week, increasing to 20–30 mg/d, with a maximum of 40 mg/d.[34]


Citalopram is frequently used off-label to treat anxiety, panic disorder, dysthymia[35] premenstrual dysphoric disorder, body dysmorphic disorder and obsessive–compulsive disorder.[12]

It has been shown to be effective in 85% of patients with GAD (generalized anxiety disorder), including some who had failed with other SSRIs[36] It also appears to be as effective as fluvoxamine and paroxetine in obsessive-compulsive disorder.[37] Some data suggests the effectiveness of intravenous infusion of citalopram in resistant OCD.[38] Citalopram 40 mg/d is well tolerated and as effective as moclobemide in social anxiety disorder.[39] There are studies suggesting that citalopram can be useful in reducing aggressive and impulsive behavior.[40][41] It appears to be superior to placebo for behavioural disturbances associated with dementia.[42] It has also been used successfully for hypersexuality in early Alzheimer’s disease.[43]

A meta analysis, including studies with fluoxetine, paroxetine, sertraline, escitalopram and citalopram versus placebo, showed that SSRIs are effective in reducing symptoms of premenstrual syndrome (PMS), whether taken continuously or just in the luteal phase.[44] Citalopram has produced a modest reduction in alcoholic drink intake and increase in drink-free days in studies of alcoholics, possibly by decreasing desire or reducing the reward.[45]

Citalopram has been found to reduce the symptoms of diabetic neuropathy.[23]

While on its own citalopram is less effective than amitriptyline in the prevention of migraines, in refractory cases combination therapy may be more effective.[24]

Citalopram and other SSRIs can be used to treat hot flashes.[25]:107

A 2009 multisite randomized controlled study found no benefit and some adverse effects in autistic children from citalopram, raising doubts whether SSRIs are effective for treating repetitive behavior in children with autism.[26]

Some research suggests that citalopram interacts with cannabinoid protein-couplings in the rat brain, and this is put forward as a potential cause of some of the drug's antidepressant effect.[27]


Citalopram is typically taken in one dose, either in the morning or evening. Citalopram can be taken with or without food. The absorption of citalopram does not increase when taken with food,[1] but doing so can help prevent nausea. Nausea is often caused when the 5HT3 receptors actively absorb free serotonin, as this receptor is present within the digestive tract.[46] The 5HT3 receptors stimulate vomiting. This side effect, if present, should subside as the body adjusts to the medication.

Citalopram is considered safe and well tolerated in the therapeutic dose range. Distinct from some other agents in its class, citalopram exhibits linear pharmacokinetics and minimal drug interaction potential, making it a better choice for the elderly or comorbid patients.[47]

Adverse effects

  • Celexa product page on Forest Laboratories web site
  • Cipramil Patient Information Leaflet
  • U.S. National Library of Medicine: Drug Information Portal - Citalopram
  • Citalopram on PubMed Health
  • Celexa page on drug price transparency web site

External links

  1. ^  


On 19 June 2013, the European Commission imposed a fine of €93.8 million on the Danish pharmaceutical company Lundbeck, plus a total of €52.2 million on several generic pharmaceutical producing companies. This was in response to Lundbeck entering an agreement with the companies to delay their sales of generic citalopram after Lundbeck's patent on the drug had expired, thus reducing competition in breach of European antitrust law.[83]

European Commission fine

  • Akarin (Denmark, Nycomed),
  • Celapram (Australia,[81] New Zealand),
  • Celexa (U.S. and Canada, Forest Laboratories, Inc.),
  • Celica (Australia[81])
  • Ciazil (Australia,[81] New Zealand),
  • Cilate (South Africa),
  • Cilift (South Africa),
  • Cimal (South America, by Roemmers and Recalcine),
  • Cipram (Turkey, Denmark, H. Lundbeck A/S),
  • Cipramil (Australia,[81] Brazil, Belgium, Finland, Germany, Netherlands, Ireland, Israel, Norway, Sweden, United Kingdom, New Zealand, South Africa, Russia),
  • Cipraned (Greece),
  • Ciprapine (Ireland),
  • Ciprotan (Ireland),
  • Citabax, Citaxin (Poland),
  • Citalec (Slovakia, Czech Republic),
  • Citalex (Iran, Serbia),
  • Citalo (Australia,[81] Egypt),
  • Citalopram (USA, United Kingdom, Denmark, Germany, Spain, Switzerland),
  • Citol (Russia),
  • Citox (Mexico),
  • Citrol (Europe and Australia[81]),
  • Citta (Brazil),
  • Clitoram (United Kingdom),
  • Dalsan (Eastern Europe),
  • Denyl (Brazil),
  • Elopram (Italy),
  • Estar (Pakistan),
  • Humorup (Argentina),
  • Humorap (Peru, Bolivia),
  • Oropram (Iceland, Actavis),
  • Opra (Russia),
  • Pram (Russia),
  • Pramcit (Pakistan),
  • Recital (Israel, Thrima Inc. for Unipharm Ltd.),
  • Sepram (Finland),
  • Seropram, (Europe)
  • Talam (Europe and Australia[81]),
  • Temperax (Chile, Peru, Argentina),
  • Vodelax (Turkey),
  • Zentius (South America, by Roemmers and Recalcine),
  • Zetalo (India),
  • Zylotex (Portugal),[82]

Citalopram is sold under the following brand-names:

Brand names

Citalopram was originally created in 1989[80] by the pharmaceutical company Lundbeck. The patent expired in 2003, allowing other companies to legally produce generic versions. Lundbeck has recently released an updated formulation called escitalopram, which is the S-enantiomer of the racemic citalopram (see b), and acquired a new patent for it. In the United States, Forest Labs manufactures and markets the drug.


Citalopram is metabolized in the liver mostly by CYP 2 C19, but also by CYP 3A4 and CYP 2D6. Metabolites desmethylcitalopram and didesmethylcitalopram are significantly less energetic and their contribution to the overall action of citalopram is negligible. The half-life of citalopram is about 35 hours. In 85% it is eliminated by the liver and in 25% by kidneys. The elimination process is slower in the elderly and in patients with hepatic or renal failure. With once daily dosing steady plasma concentrations are achieved in about a week. Potent inhibitors of CYP2C19 and 3A4 might decrease citalopram clearance.[78] It was found that tobacco smoke exposure inhibits the biotransformation of citalopram in animals; the half-life of the racemic mixture of citalopram after intragastric administration was increased by about 287%.[79]


Citalopram is sold as a racemic mixture, consisting of 50% (R)-(−)-citalopram and 50% (S)-(+)-citalopram. Only the (S)-(+) enantiomer has the desired antidepressant effect.[77] Lundbeck now markets the (S)-(+) enantiomer, the generic name of which is escitalopram. Whereas citalopram is supplied as the hydrobromide, escitalopram is sold as the oxalate salt (hydrooxalate).[1] In both cases, the salt forms of the amine make these otherwise lipophilic compounds water-soluble.

S-(+)-citalopram R-(–)-citalopram
S-(+)-citalopram R-(–)-citalopram
(S)-(+)-citalopram (R)-(–)-citalopram
-(–)-citalopram. R-(+)-citalopram and S forms (mirror images). They are termed enantiomeric, the molecule exists in (two) chirality-dimethyl-3-aminopropyl group bind. As a result of this N,N and an phenyl group4-fluoro, to which a stereocenterCitalopram has one


In the United States, citalopram, like other antidepressants, carries a black box warning stating that it may increase suicidal thinking and behavior in those under age 24.[1]


Overdosage may result in vomiting, sedation, disturbances in heart rhythm, dizziness, sweating, nausea, tremor, and rarely amnesia, confusion, coma, or convulsions.[25]:105 Overdose deaths have occurred, sometimes involving other drugs but also with citalopram as the sole agent. Citalopram and N-desmethylcitalopram may be quantized in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients or to assist in a medicolegal death investigation. Blood or plasma citalopram concentrations are usually in a range of 50-400 μg/L in persons receiving the drug therapeutically, 1000-3000 μg/L in patients who survive acute overdosage and 3–30 mg/L in those who do not survive.[73][74][75] It is the most dangerous of SSRIs in overdose.[76]


SSRI discontinuation syndrome has been reported when treatment is stopped. It includes sensory, gastrointestinal symptoms, dizziness, lethargy, and sleep disturbances, as well as psychological symptoms such as anxiety/agitation, irritability, and poor concentration.[71] Electric shock-like sensations are typical for SSRI discontinuation.[72] Tapering off citalopram therapy, as opposed to abrupt discontinuation, is recommended in order to diminish the occurrence and severity of discontinuation symptoms. Some doctors choose to switch a patient to Prozac (Fluoxetine) when discontinuing Citalopram as Fluoxetine has a much longer half-life (i.e. stays in the body longer compared to Citalopram). This may avoid many of the severe withdrawal symptoms associated with Citalopram discontinuation. This can be done either by administering a single 20 mg dose of Fluoxetine or by beginning on a low dosage of Fluoxetine and slowly tapering down. Either of these prescriptions may be written in liquid form to allow a very slow and gradual tapering down in dosage. Alternatively, a patient wishing to stop taking Citalopram may visit a compounding pharmacy where his or her prescription may be re-arranged into progressively smaller dosages.

Taking citalopram with Omeprazole may cause higher blood levels of citalopram. This is a potentially dangerous interaction, so dosage adjustments may be needed or alternatives may be prescribed.[69][70]

SSRIs, including citalopram, can increase the risk of bleeding, especially when coupled with aspirin, NSAIDs, warfarin, or other anticoagulants.[1] Citalopram is contraindicated in individuals taking MAOIs, owing to a potential for serotonin syndrome.

Tryptophan and 5-HTP are precursors to serotonin and can cause a rise in serotonin. When taken with an SSRI, such as citalopram, this can lead to levels of serotonin that can be lethal. This may also be the case when SSRI's are taken with SRA's (Serotonin Releasing Agents) such as in the case of MDMA. It is possible that SSRIs could reduce the effects associated due an SRA, due to the fact that SSRIs stop the reuptake of Serotonin by blocking SERT. This would allow less Serotonin in and out of the transporters, thus decreasing the likelihood of neurotoxic effects. However, these concerns are still disputed as the exact pharmacodynamic effects of Citalopram and MDMA have yet to be fully identified.

Citalopram should not be taken with St John's wort, tryptophan or 5-HTP as the resulting drug interaction could lead to serotonin syndrome.[65] With St John's wort, this may be caused by compounds in the plant extract reducing the efficacy of the hepatic cytochrome P450 enzymes that process citalopram.[66] It has also been suggested that such compounds, including hypericin, hyperforin and flavonoids, could have SSRI-mimetic effects on the nervous system, although this is still subject to debate.[67] One study found that Hypericum extracts had similar effects in treating moderate depression as citalopram, with fewer side effects.[68]


Citalopram and other SSRIs can induce a mixed state, especially in those with undiagnosed bipolar disorder.[25]:105

Antidepressant exposure (including citalopram) during pregnancy is associated with shorter duration of gestation (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by <0.4 points). Antidepressant exposure is not associated with an increased risk of spontaneous abortion.[61][62] It is uncertain whether there is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy.[63][64]

Exposure in pregnancy

As with other SSRI’s, citalopram can cause an increase in serum prolactin level.[58] Citalopram has no significant effect on insulin sensitivity in women of reproductive age [59] and no changes in glycaemic control were seen in another trial.[60]

Endocrine effects

Citalopram appears safe after the MI (myocardial infarction) and response to citalopram and mirtazapine may improve mortality after the MI [57] Although QTc prolongation warning must be taken into account especially in case of acute myocardial infarction, heart failure decompensation, in patients with bradycardia, low potassium and magnesium levels and in case of dose higher than 40 mg.[52][56]

It is clear that randomised investigation is still required in this field. Another large study found no elevated risks of ventricular arrhythmia or all-cause, cardiac, or noncardiac mortality associated with citalopram dosages >40 mg/day. Higher dosages were associated with fewer adverse outcomes, and similar findings were observed for a comparison medication, sertraline, not subject to the FDA warning. Based on these results the authors suggest that continued merit of the FDA warning should be considered.[56]

In August 2011, the US Food and Drug Administration (FDA) announced that “Citalopram causes dose-dependent QT interval prolongation. Citalopram should no longer be prescribed at doses greater than 40 mg per day”.[52] Further clarification issued in March 2012[53] restricted the maximum dose to 20 mg for subgroups of patients, including those older than 60 years and those taking an inhibitor of cytochrome P450 2 C19.7 This change, affecting the most widely prescribed antidepressant in the US, left clinicians unclear about appropriate next-step strategies because of the lack of data comparing citalopram with other antidepressants. In a cross-sectional study using electronic health records with almost 40,000 participants modest dose dependent QTc prolongation was confirmed. It was also true for escitalopram and amitriptyline[54] although the effect sizes were small and there is no epidemiological evidence for higher risk of cardiac arythmia.[55]

Abnormal heart rhythm QTc prolongation

Withdrawal symptoms can occur when this medicine is suddenly stopped. These include paraesthesiae, sleeping problems such as difficulty sleeping and intense dreams, feeling dizzy, agitated or anxious, nausea, vomiting, tremors, confusion, sweating, headache, diarrhoea, palpitations, changes in emotions, irritability, and eye or eyesight problems. Treatment with citalopram should be reduced gradually when treatment is finished.

Common side effects of citalopram include dry mouth,[1] increased sweating, trembling, diarrhea, excessive yawning, and fatigue. Less common side effects include bruxism, vomiting, cardiac arrhythmia, blood pressure changes, dilated pupils, anxiety, mood swings, headache and dizziness. Rare side effects include convulsions, hallucinations, severe allergic reactions and photosensitivity.[1] If sedation occurs, the dose may be taken at bedtime rather than in the morning. There is data suggesting that citalopram may cause nightmares.[51]

Citalopram theoretically causes side effects by increasing the concentration of serotonin in other parts of the body (e.g., the intestines). Other side effects, such as increased apathy and emotional flattening, may be caused by the decrease in dopamine release that is associated with increased serotonin. Citalopram is also a mild antihistamine, which may be responsible for some of its sedating properties.[25]:104

[50]. One study showed however that when remission of major depressive disorder is achieved, quality of life is reported to be higher in spite of sexual side sexual dysfunction This is known as [49] are also possible. Although usually reversible, in some people these sexual side effects become permanent after the drug has been completely withdrawn.anhedonia loss of or decreased response to sexual stimuli, and ejaculatory [48]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.